Contents

Search

dolasetron (Anzemet)

Tradename: Anzemet (FDA approved 2003) Indications: 1) nausea/vomiting associated with chemotherapy (FDA recommends against its use in this context) [2] 2) pre-operative nausea/vomiting Dosage: Oral & injection Adverse effects: 1) headache 2) fever (with injection) 3) diarrhea 4) bradycardia 5) QT prolongation - torsades de pointes (with injection) Mechanism of action: -> 5HT3 receptor antagonist

General

anti-emetic serotonin antagonist

Database Correlations

PUBCHEM correlations

References

  1. Prescriber's Letter 11(6):34 2004
  2. FDA MedWatch Dec 17, 2010 Anzemet (dolasetron mesylate): Drug Safety Communication - Reports of Abnormal Heart Rhythms http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm237341.htm
  3. http://www.Anzemet.com